and Falkson, G.: Extended survival and remission rates in metastatic breast cancer. Cancer 27: 300–303 (1971).Van Dyk JJ, Falkson G. Extended survival and remission rates in metastatic breast cancer. Cancer 1971; 27:300-303.Van Dyck JJ, Falkson G (1971) Extended survival and remission...
Chia, S. K., Speers, C. H., D’yachkova, Y., Kang, A., Malfair-Taylor, S., Barnett, J. et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer.Cancer110, 973–979 (2007). ArticlePubMedGoogle ...
The median survival of women with metastatic breast cancer (MBC) is 18–24 months, and fewer than 5% are alive and disease free at 5 years. We report toxicity and survival in a cohort of MBC patients receiving high-dose chemotherapy (HDC) with autologous
The study was published online on May 18 in Cancer Epidemiology, Biomarkers and Prevention. The researchers also reported that 5-year relative overall survival rates increased across all age groups. For example, the 5-year rate among women aged 15 to 49 years who were initially diagnosed with ...
Between 1991 and 1995, further 752 and 632 female patients with metastatic breast cancer were extracted respectively from the Connecticut and San Francisco-Oakland registries. The data were analyzed to estimate the 15-year cause-specific survival rates before the year 2005./p pResults/p pThe 5-...
2013. Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years. Cancer 119:1140-1148.Tevaarwerk AJ, Gray RJ, Schneider BP, Smith ML, Wagner LI, Fetting JH, et al. Survival in patients with metastatic ...
The primary objective of the present study was to evaluate the prognostic impact of BMI at MBC diagnosis on OS of women with metastatic breast cancer. The other objectives were to assess patient characteristics by BMI category, first-line progression-free survival (PFS), and impact of BMI on ...
Real-world 1-year survival analysis of patients with metastatic breast cancer with liver or lung metastasis treated with eribulin, gemcitabine or capecitabine - ScienceDirectBackground Pooled analyses from 2 phase III trials of patients (pts) with metastatic breast cancer (mBC) treated with eribulin...
Patients with metastatic breast cancer have traditionally been considered incurable with conventional treatment. However, 5–10% of those patients survive more than 5years, and 2–5% survive more than 10years. Recent studies suggest that the survival of patients with metastatic breast cancer has been...
overall survivalprogression-free survivaltaxane resistanceanthracycline resistanceMetastatic breast cancer is considered incurable. Despite effective response rates achieved with anthracycline or taxane anticancer drugs, cancers in approximately one third of patients fail to respond to first-line treatment with ...